Mediwound (NASDAQ:MDWD) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.05, Fidelity Earnings reports. Mediwound had a net margin of 18.46% and a negative return on equity of 71.14%. The firm had revenue of $4.44 million for the quarter, compared to analysts’ expectations of $4.25 million.
NASDAQ MDWD opened at $2.02 on Friday. Mediwound has a 12 month low of $1.44 and a 12 month high of $4.65. The company’s 50 day moving average is $1.84 and its two-hundred day moving average is $2.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.28 and a current ratio of 3.43.
MDWD has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Mediwound from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Thursday. Oppenheimer initiated coverage on shares of Mediwound in a research note on Monday, May 18th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.50 price objective on shares of Mediwound in a research note on Thursday.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
See Also: What is a management fee?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.